J. Patel

Antitumor efficacy of PD-1 blocking antibody is enhanced through liposomal delivery and myeloid immune modulation.

Systemic monoclonal antibody therapy against the PD-1 immune checkpoint (anti-PD1) is efficacious in less than 40% of patients with solid tumors. Beyond T-cells, PD-1 is expressed on myeloid populations such as monocytes, dendritic cells, myeloid progenitors, and tumor-associated macrophages (TAMs) that also have a pro...